Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Aurora, ColoradoAges 12–39 - NCT06163391RecruitingPhase 1
SOT201 for advanced solid tumors
This trial tests a new drug called SOT201 for people with advanced solid cancers that have stopped responding to other treatments. It helps the immune system fight the cancer more effectively.
Houston, TexasAges 18 years+ - NCT06165302Recruiting
Exercise study for men with advanced prostate cancer
This trial tests whether a structured exercise program can help men with metastatic prostate cancer who are on hormone therapy. It looks at changes in cancer cells and overall well-being.
Baltimore, MarylandAges 18–80 - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT06171139Recruiting
Genetic counseling tool for Black men with prostate cancer
This study tests a new tool to help Black or African American men with prostate cancer understand genetic testing options. The goal is to improve counseling and decision-making about tumor genetic testing.
San Francisco, CaliforniaAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06174987RecruitingPhase 3
Extended access study for patients benefiting from DS drugs
This study allows people who are already in a Daiichi Sankyo trial and getting benefit from the study drug to continue receiving it safely. It monitors long-term safety for those who have not had their cancer worsen.
Miami, FloridaAges 18 years+ - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT06177015RecruitingPhase 3
Darolutamide with chemo for metastatic prostate cancer
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Nanjing, JiangsuAges 40–80 - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT06184698RecruitingPhase 2
Liposomal irinotecan, chemotherapy, and bevacizumab for advanced colorectal cancer
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Shijiazhuang, HebeiAges 18–75 - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06200558Recruiting
Study of treatments for advanced prostate cancer
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Province of Macerata, MacerataAges 18 years+ - NCT06201234RecruitingPhase 2
Adding elacestrant to olaparib for advanced HR+/HER2- breast cancer
This trial tests if adding a new oral medicine (elacestrant) to a standard PARP inhibitor (olaparib) works better for people with advanced or metastatic HR+/HER2- breast cancer who have a BRCA1 or BRCA2 gene mutation. The goal is to see if the combination can help control the cancer longer.
Stuttgart, Baden-WurttembergAges 18 years+ - NCT06202001RecruitingPhase 1/Phase 2
Three-drug combo for metastatic colorectal cancer as second treatment
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
BeijingAges 18–70 - NCT06202261RecruitingPhase 1/Phase 2
Study of TQB2930 for breast cancer that has returned or spread
This trial tests a new drug called TQB2930 alone or with other treatments for people with recurrent or metastatic breast cancer. It may help if you have a type of breast cancer called HER2-positive and have not had many prior treatments for advanced disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06204991RecruitingPhase 1
T-cell therapy for advanced melanoma
This trial tests a new treatment called ADP-TILIL7 for people with advanced melanoma. It uses your own immune cells (T-cells) that are taken from a tumor, multiplied in a lab, and then given back to you to fight the cancer. The goal is to see if this treatment is safe and works better than standard options.
HerlevAges 18–75 - NCT06207734RecruitingPhase 2
Stopping CDK4/6 inhibitors in advanced breast cancer
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
BerlinAges 18 years+ - NCT06208397Recruiting
MRI study to understand liver tumor growth patterns
This trial uses MRI scans to study how colorectal cancer that has spread to the liver grows. It may help doctors choose better treatments.
Shenyang, LiaoningAges 18–80 - NCT06211257Recruiting
Digital info vs standard leaflets for advanced sarcoma
This trial is testing a digital tool (like videos or online info) to help people with advanced sarcoma understand their treatment better. It compares the digital tool to standard printed leaflets to see which improves understanding and wellbeing.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,367 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.